Hypothalamic–pituitary–adrenal axis multiple and organ dysfunction syndrome in critical illness: A special focus on arginine-vasopressin and apelin

References

• Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303–10
   PubMed Web of Science ®Google Scholar
• Schroeder S, Wichers M, Klingmuller D, Hofer M, Lehmann LE, von Spiegel T, et al. The hypothalamic-pituitary-adrenal axis of patients with severe sepsis: altered response to corticotropin-releasing hormone. Crit Care Med 2001; 29: 310–6
   PubMed Web of Science ®Google Scholar
• Russell JA, Walley KR, Singer J, Gordon AC, Hebert PC, Cooper DJ, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008; 358: 877–87
   PubMed Web of Science ®Google Scholar
• Parrillo JE. Septic shock–-vasopressin, norepinephrine, and urgency. N Engl J Med 2008; 358: 954–6
   Google Scholar
• Bernard GR, Wheeler AP, Russell JA, Schein R, Summer WR, Steinberg KP, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med 1997; 336: 912–28
   PubMed Web of Science ®Google Scholar
• Maxime V, Siami S, Annane D. Metabolism modulators in sepsis: the abnormal pituitary response. Crit Care Med 2007; 35: S596–601
   Google Scholar
• Betancur C, Borrell J, Guaza C. Cytokine regulation of corticosteroid receptors in the rat hippocampus: effects of interleukin-1, interleukin-6, tumor necrosis factor and lipopolysaccharide. Neuroendocrinology 1995; 62: 47–54
   Google Scholar
• Imura H, Fukata J. Endocrine-paracrine interaction in communication between the immune and endocrine systems. Activation of the hypothalamic-pituitary-adrenal axis in inflammation. Eur J Endocrinol 1994; 130: 32–7
   PubMedGoogle Scholar
• Sternberg EM. Neuroendocrine factors in susceptibility to inflammatory disease: focus on the hypothalamic-pituitary-adrenal axis. Horm Res 1995; 43: 159–61
   Google Scholar
• Elenkov IJ, Chrousos GP. Stress system—organization, physiology and immunoregulation. Neuroimmunomodulation 2006; 13: 257–67
   PubMed Web of Science ®Google Scholar
• Pinsky MR, Vincent JL, Deviere J, Alegre M, Kahn RJ, Dupont E. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest 1993; 103: 565–75
   PubMed Web of Science ®Google Scholar
• Thijs LG, Hack CE. Time course of cytokine levels in sepsis. Intensive Care Med 1995; 21(Suppl 2)S258–63
   Google Scholar
• Loisa P, Rinne T, Kaukinen S. Adrenocortical function and multiple organ failure in severe sepsis. Acta Anaesthesiol Scand 2002; 46: 145–51
   PubMedGoogle Scholar
• Abraham E, Singer M. Mechanisms of sepsis-induced organ dysfunction. Crit Care Med 2007; 35: 2408–16
   PubMed Web of Science ®Google Scholar
• Marik PE, Zaloga GP. Adrenal insufficiency in the critically ill: a new look at an old problem. Chest 2002; 122: 1784–96
   PubMed Web of Science ®Google Scholar
• Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288: 862–71
   PubMed Web of Science ®Google Scholar
• Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644–55
   PubMed Web of Science ®Google Scholar
• Melby JC, Spink WW. Comparative studies on adrenal cortical function and cortisol metabolism in healthy adults and in patients with shock due to infection. J Clin Invest 1958; 37: 1791–8
   PubMed Web of Science ®Google Scholar
• Parker LN, Levin ER, Lifrak ET. Evidence for adrenocortical adaptation to severe illness. J Clin Endocrinol Metab 1985; 60: 947–52
   PubMed Web of Science ®Google Scholar
• Drucker D, McLaughlin J. Adrenocortical dysfunction in acute medical illness. Crit Care Med 1986; 14: 789–91
   PubMedGoogle Scholar
• Reincke M, Allolio B, Wurth G, Winkelmann W. The hypothalamic-pituitary-adrenal axis in critical illness: response to dexamethasone and corticotropin-releasing hormone. J Clin Endocrinol Metab 1993; 77: 151–6
   PubMed Web of Science ®Google Scholar
• Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1995; 332: 1351–62
   PubMed Web of Science ®Google Scholar
• Aygen B, Inan M, Doganay M, Kelestimur F. Adrenal functions in patients with sepsis. Exp Clin Endocrinol Diabetes 1997; 105: 182–6
   PubMed Web of Science ®Google Scholar
• Bouachour G, Tirot P, Gouello JP, Mathieu E, Vincent JF, Alquier P. Adrenocortical function during septic shock. Intensive Care Med 1995; 21: 57–62
   PubMed Web of Science ®Google Scholar
• Jurney TH, Cockrell JL, Jr, Lindberg JS, Lamiell JM, Wade CE. Spectrum of serum cortisol response to ACTH in ICU patients. Correlation with degree of illness and mortality. Chest 1987; 92: 292–5
   PubMed Web of Science ®Google Scholar
• Span LF, Hermus AR, Bartelink AK, Hoitsma AJ, Gimbrere JS, Smals AG, et al. Adrenocortical function: an indicator of severity of disease and survival in chronic critically ill patients. Intensive Care Med 1992; 18: 93–6
   PubMed Web of Science ®Google Scholar
• Vermes I, Beishuizen A, Hampsink RM, Haanen C. Dissociation of plasma adrenocorticotropin and cortisol levels in critically ill patients: possible role of endothelin and atrial natriuretic hormone. J Clin Endocrinol Metab 1995; 80: 1238–42
   PubMed Web of Science ®Google Scholar
• Sibbald WJ, Short A, Cohen MP, Wilson RF. Variations in adrenocortical responsiveness during severe bacterial infections. Unrecognized adrenocortical insufficiency in severe bacterial infections. Ann Surg 1977; 186: 29–33
   PubMed Web of Science ®Google Scholar
• Van der Voort PH, Gerritsen RT, Bakker AJ, Boerma EC, Kuiper MA, de Heide L. HDL-cholesterol level and cortisol response to synacthen in critically ill patients. Intensive Care Med 2003; 29: 2199–203
   Google Scholar
• Annane D. Corticosteroids for sepsis: controversial forever?. J Crit Care 2007; 22: 329–30
   Google Scholar
• Thomas Z, Fraser GL. An update on the diagnosis of adrenal insufficiency and the use of corticotherapy in critical illness. Ann Pharmacother 2007; 41: 1456–65
   Google Scholar
• Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, et al. N Engl J Med 2008; 358: 111–24
   PubMed Web of Science ®Google Scholar
• Gaillard RC, Spinedi E, Chautard T, Pralong FP. Cytokines, leptin, and the hypothalamo-pituitary-adrenal axis. Ann N Y Acad Sci 2000; 917: 647–57
   PubMed Web of Science ®Google Scholar
• Bornstein SR, Chrousos GP. Clinical review 104: adrenocorticotropin (ACTH)- and non-ACTH-mediated regulation of the adrenal cortex: neural and immune inputs. J Clin Endocrinol Metab 1999; 84: 1729–36
   PubMed Web of Science ®Google Scholar
• Chrousos GP. The stress response and immune function: clinical implications. The 1999 Novera H. Spector Lecture. Ann N Y Acad Sci 2000;917:38–67.
   PubMed Web of Science ®Google Scholar
• Sharshar T, Carlier R, Blanchard A, Feydy A, Gray F, Paillard M, et al. Depletion of neurohypophyseal content of vasopressin in septic shock. Crit Care Med 2002; 30: 497–500
   PubMed Web of Science ®Google Scholar
• Holmes CL, Patel BM, Russell JA, Walley KR. Physiology of vasopressin relevant to management of septic shock. Chest 2001; 120: 989–1002
   PubMed Web of Science ®Google Scholar
• Landry DW, Levin HR, Gallant EM, Ashton RC, Jr, Seo S, D'Alessandro D, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997; 95: 1122–5
   PubMed Web of Science ®Google Scholar
• Sharshar T, Blanchard A, Paillard M, Raphael JC, Gajdos P, Annane D. Circulating vasopressin levels in septic shock. Crit Care Med 2003; 31: 1752–8
   PubMed Web of Science ®Google Scholar
• Saavedra JM, Benicky J. Brain and peripheral angiotensin II play a major role in stress. Stress 2007; 10: 185–93
   PubMed Web of Science ®Google Scholar
• Tsutsumi K, Saavedra JM. Characterization and development of angiotensin II receptor subtypes (AT1 and AT2) in rat brain. Am J Physiol 1991; 261: R209–16
   PubMed Web of Science ®Google Scholar
• Tsutsumi K, Saavedra JM. Angiotensin-II receptor subtypes in median eminence and basal forebrain areas involved in regulation of pituitary function. Endocrinology 1991; 129: 3001–8
   PubMed Web of Science ®Google Scholar
• Aguilera G, Young WS, Kiss A, Bathia A. Direct regulation of hypothalamic corticotropin-releasing-hormone neurons by angiotensin II. Neuroendocrinology 1995; 61: 437–44
   PubMed Web of Science ®Google Scholar
• Jezova D, Ochedalski T, Kiss A, Aguilera G. Brain angiotensin II modulates sympathoadrenal and hypothalamic pituitary adrenocortical activation during stress. J Neuroendocrinol 1998; 10: 67–72
   PubMed Web of Science ®Google Scholar
• Armando I, Volpi S, Aguilera G, Saavedra JM. Angiotensin II AT1 receptor blockade prevents the hypothalamic corticotropin-releasing factor response to isolation stress. Brain Res 2007; 1142: 92–9
   Google Scholar
• Kyrou I, Chrousos GP, Tsigos C. Stress, visceral obesity, and metabolic complications. Ann N Y Acad Sci 2006; 1083: 77–110
   PubMed Web of Science ®Google Scholar
• Aguilera G, Kiss A, Luo X. Increased expression of type 1 angiotensin II receptors in the hypothalamic paraventricular nucleus following stress and glucocorticoid administration. J Neuroendocrinol 1995; 7: 775–83
   PubMed Web of Science ®Google Scholar
• Castren E, Saavedra JM. Angiotensin II receptors in paraventricular nucleus, subfornical organ, and pituitary gland of hypophysectomized, adrenalectomized, and vasopressin-deficient rats. Proc Natl Acad Sci U S A 1989; 86: 725–9
   PubMed Web of Science ®Google Scholar
• Laesser M, Oi Y, Ewert S, Fandriks L, Aneman A. The angiotensin II receptor blocker candesartan improves survival and mesenteric perfusion in an acute porcine endotoxin model. Acta Anaesthesiol Scand 2004; 48: 198–204
   PubMed Web of Science ®Google Scholar
• Dunser MW, Hasibeder WR, Wenzel V, Schwarz S, Ulmer H, Knotzer H, et al. Endocrinologic response to vasopressin infusion in advanced vasodilatory shock. Crit Care Med 2004; 32: 1266–71
   Google Scholar
• Mutlu GM, Factor P. Role of vasopressin in the management of septic shock. Intensive Care Med 2004; 30: 1276–91
   PubMed Web of Science ®Google Scholar
• Aguilera G, Rabadan-Diehl C. Vasopressinergic regulation of the hypothalamic-pituitary-adrenal axis: implications for stress adaptation. Regul Pept 2000; 96: 23–9
   PubMed Web of Science ®Google Scholar
• Guillon G, Balestre MN, Chouinard L, Gallo-Payet N. Involvement of distinct G-proteins in the action of vasopressin on rat glomerulosa cells. Endocrinology 1990; 126: 1699–708
   Google Scholar
• Gallo-Payet N, Guillon G. Regulation of adrenocortical function by vasopressin. Horm Metab Res 1998; 30: 360–7
   PubMed Web of Science ®Google Scholar
• Grazzini E, Boccara G, Joubert D, Trueba M, Durroux T, Guillon G, et al. Vasopressin regulates adrenal functions by acting through different vasopressin receptor subtypes. Adv Exp Med Biol 1998; 449: 325–34
   PubMed Web of Science ®Google Scholar
• Koshimizu TA, Nasa Y, Tanoue A, Oikawa R, Kawahara Y, Kiyono Y, et al. V1a vasopressin receptors maintain normal blood pressure by regulating circulating blood volume and baroreflex sensitivity. Proc Natl Acad Sci U S A 2006; 103: 7807–12
   PubMed Web of Science ®Google Scholar
• Antoni FA. Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age. Front Neuroendocrinol 1993; 14: 76–122
   PubMed Web of Science ®Google Scholar
• Lolait SJ, O'Carroll AM, Mahan LC, Felder CC, Button DC, Young WS 3rd, et al. Extrapituitary expression of the rat V1b vasopressin receptor gene. Proc Natl Acad Sci U S A 1995;92:6783–7.
   PubMed Web of Science ®Google Scholar
• Lauzier F, Levy B, Lamarre P, Lesur O. Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial. Intensive Care Med 2006; 32: 1782–9
   PubMed Web of Science ®Google Scholar
• Lolait SJ, Stewart LQ, Roper JA, Harrison G, Jessop DS, Young WS 3rd, et al. Attenuated stress response to acute lipopolysaccharide challenge and ethanol administration in vasopressin V1b receptor knockout mice. J Neuroendocrinol 2007; 19: 543–51
   PubMed Web of Science ®Google Scholar
• Oelkers W. Hyponatremia and inappropriate secretion of vasopressin (antidiuretic hormone) in patients with hypopituitarism. N Engl J Med 1989; 321: 492–6
   PubMedGoogle Scholar
• Papanek PE, Raff H. Chronic physiological increases in cortisol inhibit the vasopressin response to hypertonicity in conscious dogs. Am J Physiol 1994; 267: R1342–9
   Google Scholar
• Chagnon F, Vaidya V, Bonventre J, Bernard A, Guindi C, Lesur O. Modulation of AQP-2/V2R kidney expression and tubular injury following endotoxin (LPS) challenge. Crit Care Med 2008; In press.
   Google Scholar
• Chassin C, Hornef MW, Bens M, Lotz M, Goujon JM, Vimont S, et al. Hormonal control of the renal immune response and antibacterial host defense by arginine vasopressin. J Exp Med 2007; 204: 2837–52
   PubMed Web of Science ®Google Scholar
• Erfurth EM, Hedner P, Lundin S, Ekman R. Release of prolactin as well as adrenocorticotropin after administration of arginine-vasopressin to healthy men. Horm Metab Res 1996; 28: 599–602
   Google Scholar
• Giusti-Paiva A, De Castro M, Antunes-Rodrigues J, Carnio EC. Inducible nitric oxide synthase pathway in the central nervous system and vasopressin release during experimental septic shock. Crit Care Med 2002; 30: 1306–10
   PubMed Web of Science ®Google Scholar
• Jochberger S, Mayr VD, Luckner G, Wenzel V, Ulmer H, Schmid S, et al. Serum vasopressin concentrations in critically ill patients. Crit Care Med 2006; 34: 293–9
   PubMedGoogle Scholar
• Jochberger S, Morgenthaler NG, Mayr VD, Luckner G, Wenzel V, Ulmer H, et al. Copeptin and arginine vasopressin concentrations in critically ill patients. J Clin Endocrinol Metab 2006; 91: 4381–6
   PubMed Web of Science ®Google Scholar
• Wilson MF, Brackett DJ, Tompkins P, Benjamin B, Archer LT, Hinshaw LB. Elevated plasma vasopressin concentrations during endotoxin and E. coli shock. Adv Shock Res 1981; 6: 15–26
   PubMedGoogle Scholar
• Brackett DJ, Schaefer CF, Tompkins P, Fagraeus L, Peters LJ, Wilson MF. Evaluation of cardiac output, total peripheral vascular resistance, and plasma concentrations of vasopressin in the conscious, unrestrained rat during endotoxemia. Circ Shock 1985; 17: 273–84
   PubMedGoogle Scholar
• Carnio EC, Stabile AM, Batalhao ME, Silva JS, Antunes-Rodrigues J, Branco LG, et al. Vasopressin release during endotoxaemic shock in mice lacking inducible nitric oxide synthase. Pflugers Arch 2005; 450: 390–4
   Google Scholar
• Russell JA. Vasopressin in vasodilatory and septic shock. Curr Opin Crit Care 2007; 13: 383–91
   Google Scholar
• Landry DW, Oliver JA. The ATP-sensitive K+ channel mediates hypotension in endotoxemia and hypoxic lactic acidosis in dog. J Clin Invest 1992; 89: 2071–4
   PubMed Web of Science ®Google Scholar
• Bucher M, Hobbhahn J, Taeger K, Kurtz A. Cytokine-mediated downregulation of vasopressin V(1A) receptors during acute endotoxemia in rats. Am J Physiol Regul Integr Comp Physiol 2002; 282: R979–84
   Google Scholar
• Morgenthaler NG, Muller B, Struck J, Bergmann A, Redl H, Christ-Crain M. Copeptin, a stable peptide of the arginine vasopressin precursor, is elevated in hemorrhagic and septic shock. Shock 2007; 28: 219–26
   PubMed Web of Science ®Google Scholar
• Muller B, Morgenthaler N, Stolz D, Schuetz P, Muller C, Bingisser R, et al. Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Invest 2007; 37: 145–52
   PubMed Web of Science ®Google Scholar
• Stolz D, Christ-Crain M, Morgenthaler NG, Leuppi J, Miedinger D, Bingisser R, et al. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest 2007; 131: 1058–67
   PubMed Web of Science ®Google Scholar
• Seligman R, Papassotiriou J, Morgenthaler NG, Meisner M, Teixeira PJ. Copeptin, a novel prognostic biomarker in ventilator-associated pneumonia. Crit Care 2008; 12: R11
   PubMed Web of Science ®Google Scholar
• Landry DW, Levin HR, Gallant EM, Seo S, D'Alessandro D, Oz MC, et al. Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med 1997; 25: 1279–82
   PubMed Web of Science ®Google Scholar
• Barrett LK, Orie NN, Taylor V, Stidwill RP, Clapp LH, Singer M. Differential effects of vasopressin and norepinephrine on vascular reactivity in a long-term rodent model of sepsis. Crit Care Med 2007; 35: 2337–43
   Google Scholar
• Luckner G, Mayr VD, Jochberger S, Wenzel V, Ulmer H, Hasibeder WR, et al. Comparison of two dose regimens of arginine vasopressin in advanced vasodilatory shock. Crit Care Med 2007; 35: 2280–5
   Google Scholar
• Morales DL, Garrido MJ, Madigan JD, Helman DN, Faber J, Williams MR, et al. A double-blind randomized trial: prophylactic vasopressin reduces hypotension after cardiopulmonary bypass. Ann Thorac Surg 2003; 75: 926–30
   PubMed Web of Science ®Google Scholar
• Argenziano M, Choudhri A, Oz M, Rose E, Smith C, Landry D. A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. Circulation 1997;96(9 Suppl):286–90.
   Google Scholar
• Dunser MW, Mayr AJ, Ulmer H, Ritsch N, Knotzer H, Pajk W, et al. The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: a retrospective analysis. Anesth Analg 2001; 93: 7–13
   PubMed Web of Science ®Google Scholar
• Dunser MW, Mayr AJ, Ulmer H, Knotzer H, Sumann G, Pajk W, et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation 2003; 107: 2313–9
   PubMed Web of Science ®Google Scholar
• Morales DL, Gregg D, Helman DN, Williams MR, Naka Y, Landry DW, et al. Arginine vasopressin in the treatment of 50 patients with postcardiotomy vasodilatory shock. Ann Thorac Surg 2000; 69: 102–6
   PubMed Web of Science ®Google Scholar
• Holmes CL, Walley KR, Chittock DR, Lehman T, Russell JA. The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Care Med 2001; 27: 1416–21
   PubMed Web of Science ®Google Scholar
• Malay MB, Ashton JL, Dahl K, Savage EB, Burchell SA, Ashton RC, Jr, et al. Heterogeneity of the vasoconstrictor effect of vasopressin in septic shock. Crit Care Med 2004; 32: 1327–31
   PubMed Web of Science ®Google Scholar
• Dunser MW, Mayr AJ, Tur A, Pajk W, Barbara F, Knotzer H, et al. Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: incidence and risk factors. Crit Care Med 2003; 31: 1394–8
   PubMed Web of Science ®Google Scholar
• Van Haren FM, Rozendaal FW, van der Hoeven JG. The effect of vasopressin on gastric perfusion in catecholamine-dependent patients in septic shock. Chest 2003; 124: 2256–60
   PubMed Web of Science ®Google Scholar
• Klinzing S, Simon M, Reinhart K, Bredle DL, Meier-Hellmann A. High-dose vasopressin is not superior to norepinephrine in septic shock. Crit Care Med 2003; 31: 2646–50
   PubMed Web of Science ®Google Scholar
• Farand P, Hamel M, Lauzier F, Plante GE, Lesur O. Review article: organ perfusion/permeability-related effects of norepinephrine and vasopressin in sepsis. Can J Anaesth 2006; 53: 934–46
   Google Scholar
• Guzman JA, Rosado AE, Kruse JA. Vasopressin vs norepinephrine in endotoxic shock: systemic, renal, and splanchnic hemodynamic and oxygen transport effects. J Appl Physiol 2003; 95: 803–9
   PubMed Web of Science ®Google Scholar
• Dunser MW, Fries DR, Schobersberger W, Ulmer H, Wenzel V, Friesenecker B, et al. Does arginine vasopressin influence the coagulation system in advanced vasodilatory shock with severe multiorgan dysfunction syndrome?. Anesth Analg 2004; 99: 201–6
   PubMed Web of Science ®Google Scholar
• Filep J, Rosenkranz B. Mechanism of vasopressin-induced platelet aggregation. Thromb Res 1987; 45: 7–15
   PubMed Web of Science ®Google Scholar
• Levy B, Vallee C, Lauzier F, Plante GE, Mansart A, Mallie JP, et al. Comparative effects of vasopressin, norepinephrine, and L-canavanine, a selective inhibitor of inducible nitric oxide synthase, in endotoxic shock. Am J Physiol Heart Circ Physiol 2004; 287: H209–15
   Google Scholar
• Patel BM, Chittock DR, Russell JA, Walley KR. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 2002; 96: 576–82
   PubMed Web of Science ®Google Scholar
• Leone M, Boyle WA. Decreased vasopressin responsiveness in vasodilatory septic shock-like conditions. Crit Care Med 2006; 34: 1126–30
   Google Scholar
• Sun Q, Dimopoulos G, Nguyen DN, Tu Z, Nagy N, Hoang AD, et al. Low-dose vasopressin in the treatment of septic shock in sheep. Am J Respir Crit Care Med 2003; 168: 481–6
   PubMed Web of Science ®Google Scholar
• Ertmer C, Bone HG, Morelli A, Van Aken H, Erren M, Lange M, et al. Methylprednisolone reverses vasopressin hyporesponsiveness in ovine endotoxemia. Shock 2007; 27: 281–8
   Google Scholar
• Karmazyn M, Manku MS, Horrobin DF. Changes of vascular reactivity induced by low vasopressin concentrations: interactions with cortisol and lithium and possible involvement of prostaglandins. Endocrinology 1978; 102: 1230–6
   Google Scholar
• Aboab J, Polito A, Orlikowski D, Sharshar T, Castel M, Annane D. Hydrocortisone effects on cardiovascular variability in septic shock: a spectral analysis approach. Crit Care Med 2008; 36: 1481–6
   Google Scholar
• Callewaere C, Banisadr G, Desarmenien MG, Mechighel P, Kitabgi P, Rostene WH, et al. The chemokine SDF-1/CXCL12 modulates the firing pattern of vasopressin neurons and counteracts induced vasopressin release through CXCR4. Proc Natl Acad Sci U S A 2006; 103: 8221–6
   Google Scholar
• Morales D, Madigan J, Cullinane S, Chen J, Heath M, Oz M, et al. Reversal by vasopressin of intractable hypotension in the late phase of hemorrhagic shock. Circulation 1999; 100: 226–9
   PubMedGoogle Scholar
• Stroumpoulis K, Xanthos T, Rokas G, Kitsou V, Papadimitriou D, Serpetinis I, et al. Vasopressin and epinephrine in the treatment of cardiac arrest: an experimental study. Crit Care 2008; 12: R40
   PubMed Web of Science ®Google Scholar
• Mayr V, Luckner G, Jochberger S, Wenzel V, Ulmer H, Pajk W, et al. Arginine vasopressin in advanced cardiovascular failure during the post-resuscitation phase after cardiac arrest. Resuscitation 2007; 72: 35–44
   PubMed Web of Science ®Google Scholar
• Adrie C, Laurent I, Monchi M, Cariou A, Dhainaou JF, Spaulding C. Postresuscitation disease after cardiac arrest: a sepsis-like syndrome?. Curr Opin Crit Care 2004; 10: 208–12
   PubMedGoogle Scholar
• Huang L, Tang W. Vasopressor agents: old and new components. Curr Opin Crit Care 2004; 10: 183–7
   Google Scholar
• Reaux-Le Goazigo A, Alvear-Perez R, Zizzari P, Epelbaum J, Bluet-Pajot MT, Llorens-Cortes C. Cellular localization of apelin and its receptor in the anterior pituitary: evidence for a direct stimulatory action of apelin on ACTH release. Am J Physiol Endocrinol Metab 2007; 292: E7–15
   Web of Science ®Google Scholar
• Lee DK, Cheng R, Nguyen T, Fan T, Kariyawasam AP, Liu Y, et al. Characterization of apelin, the ligand for the APJ receptor. J Neurochem 2000; 74: 34–41
   PubMed Web of Science ®Google Scholar
• Japp AG, Newby DE. The apelin-APJ system in heart failure: pathophysiologic relevance and therapeutic potential. Biochem Pharmacol 2008; 75: 1882–92
   PubMed Web of Science ®Google Scholar
• Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 1998; 251: 471–6
   PubMed Web of Science ®Google Scholar
• Kleinz MJ, Davenport AP. Emerging roles of apelin in biology and medicine. Pharmacol Ther 2005; 107: 198–211
   PubMed Web of Science ®Google Scholar
• Katugampola S, Davenport A. Emerging roles for orphan G-protein-coupled receptors in the cardiovascular system. Trends Pharmacol Sci 2003; 24: 30–5
   PubMed Web of Science ®Google Scholar
• O'Dowd BF, Heiber M, Chan A, Heng HH, Tsui LC, Kennedy JL, et al. A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene 1993; 136: 355–60
   PubMed Web of Science ®Google Scholar
• Habata Y, Fujii R, Hosoya M, Fukusumi S, Kawamata Y, Hinuma S, et al. Apelin, the natural ligand of the orphan receptor APJ, is abundantly secreted in the colostrum. Biochim Biophys Acta 1999; 1452: 25–35
   PubMed Web of Science ®Google Scholar
• Hosoya M, Kawamata Y, Fukusumi S, Fujii R, Habata Y, Hinuma S, et al. Molecular and functional characteristics of APJ. @ Tissue distribution of mRNA and interaction with the endogenous ligand apelin. J Biol Chem 2000; 275: 21061–7
   PubMed Web of Science ®Google Scholar
• Reaux A, De Mota N, Skultetyova I, Lenkei Z, El Messari S, Gallatz K, et al. Physiological role of a novel neuropeptide, apelin, and its receptor in the rat brain. J Neurochem 2001; 77: 1085–96
   PubMed Web of Science ®Google Scholar
• Lee DK, George SR, O'Dowd BF. Unravelling the roles of the apelin system: prospective therapeutic applications in heart failure and obesity. Trends Pharmacol Sci 2006; 27: 190–4
   PubMed Web of Science ®Google Scholar
• Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 2002; 277: 14838–43
   PubMed Web of Science ®Google Scholar
• Burrell LM, Johnston CI, Tikellis C, Cooper ME. ACE2, a new regulator of the renin-angiotensin system. Trends Endocrinol Metab 2004; 15: 166–9
   PubMed Web of Science ®Google Scholar
• De Falco M, De Luca L, Onori N, Cavallotti I, Artigiano F, Esposito V, et al. Apelin expression in normal human tissues. In Vivo 2002; 16: 333–6
   PubMed Web of Science ®Google Scholar
• De Mota N, Lenkei Z, Llorens-Cortes C. Cloning, pharmacological characterization and brain distribution of the rat apelin receptor. Neuroendocrinology 2000; 72: 400–7
   PubMed Web of Science ®Google Scholar
• Kawamata Y, Habata Y, Fukusumi S, Hosoya M, Fujii R, Hinuma S, et al. Molecular properties of apelin: tissue distribution and receptor binding. Biochim Biophys Acta 2001; 1538: 162–71
   PubMed Web of Science ®Google Scholar
• Medhurst AD, Jennings CA, Robbins MJ, Davis RP, Ellis C, Winborn KY, et al. Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin. J Neurochem 2003; 84: 1162–72
   PubMed Web of Science ®Google Scholar
• O'Carroll AM, Selby TL, Palkovits M, Lolait SJ. Distribution of mRNA encoding B78/apj, the rat homologue of the human APJ receptor, and its endogenous ligand apelin in brain and peripheral tissues. Biochim Biophys Acta 2000; 1492: 72–80
   PubMed Web of Science ®Google Scholar
• Reaux A, Gallatz K, Palkovits M, Llorens-Cortes C. Distribution of apelin-synthesizing neurons in the adult rat brain. Neuroscience 2002; 113: 653–62
   PubMed Web of Science ®Google Scholar
• Brailoiu GC, Dun SL, Yang J, Ohsawa M, Chang JK, Dun NJ. Apelin-immunoreactivity in the rat hypothalamus and pituitary. Neurosci Lett 2002; 327: 193–7
   PubMedGoogle Scholar
• Jaszberenyi M, Bujdoso E, Telegdy G. Behavioral, neuroendocrine and thermoregulatory actions of apelin-13. Neuroscience 2004; 129: 811–6
   Google Scholar
• Taheri S, Murphy K, Cohen M, Sujkovic E, Kennedy A, Dhillo W, et al. The effects of centrally administered apelin-13 on food intake, water intake and pituitary hormone release in rats. Biochem Biophys Res Commun 2002; 291: 1208–12
   PubMed Web of Science ®Google Scholar
• Renner U, Pagotto U, Arzt E, Stalla GK. Autocrine and paracrine roles of polypeptide growth factors, cytokines and vasogenic substances in normal and tumorous pituitary function and growth: a review. Eur J Endocrinol 1996; 135: 515–32
   PubMed Web of Science ®Google Scholar
• Schwartz J, Cherny R. Intercellular communication within the anterior pituitary influencing the secretion of hypophysial hormones. Endocr Rev 1992; 13: 453–75
   PubMed Web of Science ®Google Scholar
• Edinger AL, Hoffman TL, Sharron M, Lee B, Yi Y, Choe W, et al. An orphan seven-transmembrane domain receptor expressed widely in the brain functions as a coreceptor for human immunodeficiency virus type 1 and simian immunodeficiency virus. J Virol 1998; 72: 7934–40
   PubMed Web of Science ®Google Scholar
• Devic E, Rizzoti K, Bodin S, Knibiehler B, Audigier Y. Amino acid sequence and embryonic expression of msr/apj, the mouse homolog of Xenopus X-msr and human APJ. Mech Dev 1999; 84: 199–203
   PubMed Web of Science ®Google Scholar
• Ishida J, Hashimoto T, Hashimoto Y, Nishiwaki S, Iguchi T, Harada S, et al. Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo. J Biol Chem 2004; 279: 26274–9
   PubMed Web of Science ®Google Scholar
• Cohen RA, Vanhoutte PM. Endothelium-dependent hyperpolarization. Beyond nitric oxide and cyclic GMP. Circulation 1995; 92: 3337–49
   PubMed Web of Science ®Google Scholar
• Katugampola SD, Maguire JJ, Matthewson SR, Davenport AP. [(125)I]-(Pyr(1))Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man. Br J Pharmacol 2001; 132: 1255–60
   PubMed Web of Science ®Google Scholar
• Szokodi I, Tavi P, Foldes G, Voutilainen-Myllyla S, Ilves M, Tokola H, et al. Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res 2002; 91: 434–40
   PubMed Web of Science ®Google Scholar
• Dai T, Ramirez-Correa G, Gao WD. Apelin increases contractility in failing cardiac muscle. Eur J Pharmacol 2006; 553: 222–8
   PubMed Web of Science ®Google Scholar
• Ashley EA, Powers J, Chen M, Kundu R, Finsterbach T, Caffarelli A, et al. The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. Cardiovasc Res 2005; 65: 73–82
   PubMed Web of Science ®Google Scholar
• Chong KS, Gardner RS, Morton JJ, Ashley EA, McDonagh TA. Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. Eur J Heart Fail 2006; 8: 355–60
   PubMed Web of Science ®Google Scholar
• Francia P, Salvati A, Balla C, De Paolis P, Pagannone E, Borro M, et al. Cardiac resynchronization therapy increases plasma levels of the endogenous inotrope apelin. Eur J Heart Fail 2007; 9: 306–9
   PubMed Web of Science ®Google Scholar
• Goetze JP, Rehfeld JF, Carlsen J, Videbaek R, Andersen CB, Boesgaard S, et al. Apelin: a new plasma marker of cardiopulmonary disease. Regul Pept 2006; 133: 134–8
   PubMed Web of Science ®Google Scholar
• Evora PR, Pearson PJ, Schaff HV. Arginine vasopressin induces endothelium-dependent vasodilatation of the pulmonary artery. V1-receptor-mediated production of nitric oxide. Chest 1993; 103: 1241–5
   PubMed Web of Science ®Google Scholar
• Daviaud D, Boucher J, Gesta S, Dray C, Guigne C, Quilliot D, et al. TNFalpha up-regulates apelin expression in human and mouse adipose tissue. FASEB J 2006; 20: 1528–30
   PubMed Web of Science ®Google Scholar
• Llorens-Cortes C, Beaudet A. Apelin, a neuropeptide that counteracts vasopressin secretion. Med Sci (Paris) 2005;21:741–6 ( in French).
   Google Scholar
• Berry MF, Pirolli TJ, Jayasankar V, Burdick J, Morine KJ, Gardner TJ, et al. Apelin has in vivo inotropic effects on normal and failing hearts. Circulation 2004; 110: II187–93
   PubMed Web of Science ®Google Scholar
• Chen MM, Ashley EA, Deng DX, Tsalenko A, Deng A, Tabibiazar R, et al. Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction. Circulation 2003; 108: 1432–9
   PubMed Web of Science ®Google Scholar
• Charles CJ, Rademaker MT, Richards AM. Apelin-13 induces a biphasic haemodynamic response and hormonal activation in normal conscious sheep. J Endocrinol 2006; 189: 701–10
   PubMed Web of Science ®Google Scholar
• Cheng X, Cheng XS, Pang CC. Venous dilator effect of apelin, an endogenous peptide ligand for the orphan APJ receptor, in conscious rats. Eur J Pharmacol 2003; 470: 171–5
   PubMed Web of Science ®Google Scholar
• Sorhede Winzell M, Magnusson C, Ahren B. The apj receptor is expressed in pancreatic islets and its ligand, apelin, inhibits insulin secretion in mice. Regul Pept 2005; 131: 12–7
   PubMedGoogle Scholar
• Tang SY, Xie H, Yuan LQ, Luo XH, Huang J, Cui RR, et al. Apelin stimulates proliferation and suppresses apoptosis of mouse osteoblastic cell line MC3T3-E1 via JNK and PI3-K/Akt signaling pathways. Peptides 2007; 28: 708–18
   PubMed Web of Science ®Google Scholar
• Xie H, Yuan LQ, Luo XH, Huang J, Cui RR, Guo LJ, et al. Apelin suppresses apoptosis of human osteoblasts. Apoptosis 2007; 12: 247–54
   PubMedGoogle Scholar
• Han S, Wang G, Qiu S, de la Motte C, Wang HQ, Gomez G, et al. Increased colonic apelin production in rodents with experimental colitis and in humans with IBD. Regul Pept 2007; 142: 131–7
   PubMedGoogle Scholar